The clinical spectrum of prostate cancer ranges from curable, local disease to widely metastatic, lethal cancer. Two new prostate cancer genome studies provide the first glimpse at both ends of this spectrum.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Barbieri, C.E et al. Nat. Genet. 44, 685–689 (2012).
Grasso, C.S. et al. Nature published online, doi:10.1038/nature11125 (20 May 2012).
Berger, M.F. et al. Nature 470, 214–220 (2011).
Robbins, C.M. et al. Genome Res. 21, 47–55 (2011).
Taylor, B.S. et al. Cancer Cell 18, 11–22 (2010).
Demichelis, F. et al. Genes Chromosom. Cancer 48, 366–380 (2009).
Cuzick, J. et al. Lancet Oncol. 12, 245–255 (2011).
Tomlins, S.A. et al. Nature 448, 595–599 (2007).
Shen, M.M. & Abate-Shen, C. Genes Dev. 24, 1967–2000 (2010).
Palanisamy, N. et al. Nat. Med. 16, 793–798 (2010).
Tomlins, S.A. et al. Cancer Cell 13, 519–528 (2008).
Furukawa, M., He, Y.J., Borchers, C. & Xiong, Y. Nat. Cell Biol. 5, 1001–1007 (2003).
Cuzick, J. et al. Br. J. Cancer 106, 1095–1099 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Hieronymus, H., Sawyers, C. Traversing the genomic landscape of prostate cancer from diagnosis to death. Nat Genet 44, 613–614 (2012). https://doi.org/10.1038/ng.2301
Published:
Issue date:
DOI: https://doi.org/10.1038/ng.2301
